Current management options for recurrent adrenocortical carcinoma

References

• FassnachtMLibéRKroissMAllolioBMedscapeAdrenocortical carcinoma: a clinician’s updateNat Rev Endocrinol20117632333521386792
   PubMed Web of Science ®Google Scholar
• WajchenbergBLAlbergaria PereiraMAMedoncaBBAdrenocortical Carcinoma: clinical and laboratory observationsCancer200088471173610679640
   PubMed Web of Science ®Google Scholar
• BerrutiABaudinEGelderblomHAdrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn of Oncol201223Suppl 7vii131vii13822997446
   PubMed Web of Science ®Google Scholar
• KebebewEReiffEDuhQYClarkOHMcMillanAExtent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?World J Surg200630587287816680602
   PubMed Web of Science ®Google Scholar
• KirschnerLSThe next generation of therapies for adrenocortical cancersTrends in Endocrinol Metab201223734335022626690
   PubMed Web of Science ®Google Scholar
• AbivenGCosteJGroussinLClinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patientsJ Clin Endocrinol Metab20069172650265516670169
   PubMed Web of Science ®Google Scholar
• SchulickRDBrennanMFLong-term survival after complete resection and repeat resection in patients with adrenocortical carcinomaAnn Surg Oncol19996871972610622498
   PubMed Web of Science ®Google Scholar
• StojadinovicAGhosseinRAHoosAAdrenocortical carcinoma: clinical, morphologic, and molecular characterizationJ Clin Oncol200220494195011844815
   PubMed Web of Science ®Google Scholar
• FassnachtMAllolioBClinical management of adrenocortical carcinomaBest Pract Res Clin Endocrinol Metab200923227328919500769
   PubMed Web of Science ®Google Scholar
• LauSKWeissLMThe Weiss system for evaluating adrenocortical neoplasms: 25 years laterHum Pathol200940675776819442788
   PubMed Web of Science ®Google Scholar
• AubertSWacrenierALeroyXWeiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumorsAm J Surg Pathol200226121612161912459628
   PubMed Web of Science ®Google Scholar
• SoonPSHGillAJBennDEMicroarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomasEndocr Relat Cancer200916257358319218281
   PubMed Web of Science ®Google Scholar
• SchmittAASaremaslaniPPSchmidSSRearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumorsJ Clin Endocrinol Metab1994786144414537911125
   PubMed Web of Science ®Google Scholar
• MorimotoRSatohFMurakamiOImmunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/ MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomasEndocr J20085514955 Available at: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=18187873&retmode=ref&cmd=prlinksAccessed January 14, 201318187873
   PubMed Web of Science ®Google Scholar
• GicquelCCBertagnaXXGastonVVMolecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumorsCancer Res200161186762676711559548
   PubMed Web of Science ®Google Scholar
• AssieGGiordanoTJBertheratJGene expresion profiling in adrenocortical neoplasiaMol Cell Endocrinol20123511111117 Available at: http://www.sciencedirect.com/science/article/pii/S0303720711006162Accessed February 14, 201322056416
   PubMed Web of Science ®Google Scholar
• SoonPSLibéRBennDELoss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumorsAnn Surg2008247115716418156936
   PubMed Web of Science ®Google Scholar
• PattersonEEHollowayAKWengJFojoTKebebewEMicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancyCancer201011781630163921472710
   PubMed Web of Science ®Google Scholar
• RechacheNSWangYStevensonHSDNA methylation profiling identifies global methylation differences and markers of adrenocortical tumorsJ Clin Endocrinol Metab2012976E1004E101322472567
   PubMed Web of Science ®Google Scholar
• de ReyniesAAssieGRickmanDSGene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survivalJ Clin Oncol20092771108111519139432
   PubMed Web of Science ®Google Scholar
• SchteingartDEDohertyGMGaugerPGManagement of patients with adrenal cancer: recommendations of an international consensus conferenceEndocr Relat Cancer200512366768016172199
   PubMed Web of Science ®Google Scholar
• TerzoloMAngeliAFassnachtMAdjuvant mitotane treatment for adrenocortical carcinomaN Engl J Med2007356232372238017554118
   PubMed Web of Science ®Google Scholar
• FassnachtMJohanssenSFenskeWImproved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centersJ Clin Endocrinol Metab201095114925493220668036
   PubMed Web of Science ®Google Scholar
• HuangHFojoTAdjuvant mitotane for adrenocortical cancer – a recurring controversyJ Clin Endocrinol Metab200893103730373218842984
   PubMed Web of Science ®Google Scholar
• AllolioBFassnachtMAdrenocortical carcinoma: clinical updateJ Clin Endocrinol Metab20069162027203716551738
   PubMed Web of Science ®Google Scholar
• FassnachtMAllolioBWhat is the best approach to an apparently nonmetastatic adrenocortical carcinoma?Clin Endocrinol2010735561565
   Web of Science ®Google Scholar
• University of Turin, ItalyEfficacy of Adjuvant Mitotane Treatment (ADIUVO)ClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated 2011]. Available from: http://clinicaltrials.gov/show/NCT00777244. NLM identifier: NCT00777244Accessed January 10, 2013
   Google Scholar
• LacroixAApproach to the patient with adrenocortical carcinomaJ Clin Endocrinol Metab201095114812482221051577
   PubMed Web of Science ®Google Scholar
• ArltWBiehlMTaylorAEUrine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumorsJ Clin Endocrinol Metab201196123775378421917861
   PubMed Web of Science ®Google Scholar
• KendrickMLLloydREricksonLAdrenocortical carcinoma: surgical progress or status quo?Arch Surg200113654354911343545
   PubMedGoogle Scholar
• CrucittiFBellantoneRFerranteABoscheriniMCrucittiPGroup TAIRSThe Italian registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study GroupSurgery19961191611708571201
   PubMed Web of Science ®Google Scholar
• LombardiCPRaffaelliMBoniardiMAdrenocortical carcinoma: effect of hospital volume on patient outcomeLangenbecks Arch Surg2011397220120722069043
   PubMed Web of Science ®Google Scholar
• PommierRFBrennanMFAn eleven-year experience with adrenocortical carcinomaSurgery19921129639711455321
   PubMed Web of Science ®Google Scholar
• BellantoneRFerranteABoscheriuiMRole of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical CarcinomaSurgery19971226121212189426440
   PubMed Web of Science ®Google Scholar
• FassnachtMHahnerSPolatBEfficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinomaJ Clin Endocrinol Metab200691114501450416895957
   PubMed Web of Science ®Google Scholar
• LombardiCPRaffaelliMDe CreaCOpen versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian surveySurgery201215261158116423068084
   PubMed Web of Science ®Google Scholar
• BrennanMFAdrenocortical CarcinomaCA Cancer J Clin1987376349365
   Web of Science ®Google Scholar
• DatriceNMLanganRCRipleyRTOperative management for recurrent and metastatic adrenocortical carcinomaJ Surg Oncol2011105770971322189845
   PubMed Web of Science ®Google Scholar
• MillerBSGaugerPGHammerGDDohertyGMResection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomySurgery201215261150115723158185
   PubMed Web of Science ®Google Scholar
• PercarpioBKnowltonAHRadiation therapy of adrenal cortical carcinomaActa Radiol Ther Phys Biol197615428829262490
   PubMed Web of Science ®Google Scholar
• LebastchiAHKunstmanJWCarlingTAdrenocortical Carcinoma: Current Therapeutic State-Of-The-ArtJ Oncol20122012111
   Google Scholar
• HabraMAEjazSFengLA Retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinomaJ Clin Endocrinol Metab201398119219723150683
   PubMed Web of Science ®Google Scholar
• PolatBFassnachtMPfreundnerLRadiotherapy in adrenocortical carcinomaCancer2009115132816282319402169
   PubMed Web of Science ®Google Scholar
• SabolchAFengMGriffithKHammerGDohertyGBen-JosefEAdjuvant and Definitive Radiotherapy for Adrenocortical CarcinomaInt J Radiat Oncol Biol Phys20118051477148420675074
   PubMed Web of Science ®Google Scholar
• MilgromSAGoodmanKAThe role of radiation therapy in the management of adrenal carcinoma and adrenal metastasesJ Surg Oncol2012106564765022488095
   PubMed Web of Science ®Google Scholar
• WoodBJAbrahamJHvizdaJLAlexanderHRFojoTRadiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastasesCancer200397355456012548596
   PubMed Web of Science ®Google Scholar
• IcardPGoudetPCharpenayCAdrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study groupWorld J Surg200125789189711572030
   PubMed Web of Science ®Google Scholar
• ChortisVTaylorAESchneiderPMitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacementJ Clin Endocrinol Metab201398116117123162091
   PubMed Web of Science ®Google Scholar
• HaakHRHermansJvan deVeldeCJHOptimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patientsBr J Cancer19946959479518180029
   PubMed Web of Science ®Google Scholar
• HahnerSFassnachtMMitotane for adrenocortical carcinoma treatmentCurr Opin Investig Drugs200564386394
   PubMedGoogle Scholar
• KornelyESchlagheckeRComplete remission of metastasized adrenocortical carcinoma under o,p’-DDDExp Clin Endocrinol1994102150538005209
   PubMedGoogle Scholar
• IliasIAlevizakiMPhilippouGAnastasiouESouvatzoglouASustained remission of metastatic adrenal carcinoma during long follow upJ Endocrinol Invest200124753253511508789
   PubMed Web of Science ®Google Scholar
• FassnachtMTerzoloMAllolioBCombination chemotherapy in advanced adrenocortical carcinomaN Engl J Med2012366232189219722551107
   PubMed Web of Science ®Google Scholar
• FassnachtMKreisslMCWeismannDAllolioBNew targets and therapeutic approaches for endocrine malignanciesPharmacol Ther2009123111714119374919
   PubMed Web of Science ®Google Scholar
• SperonePFerreroADaffaraFGemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II studyEndocr Relat Cancer201017244545320410174
   PubMed Web of Science ®Google Scholar
• VeytsmanINiemanLFojoTManagement of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical CarcinomaJ Clin Oncol200927274619462919667279
   PubMed Web of Science ®Google Scholar
• GaujouxSAl-AhmadieHAllenPJResection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?Ann Surg Oncol20121982643265122526905
   PubMed Web of Science ®Google Scholar
• Winkel denJOPfannschmidtJMuleyTMetastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patientsAnn Thorarc Surg201192619651970
   Web of Science ®Google Scholar
• MihaiRIacoboneMMakayOOutcome of operation in patients with adrenocortical cancer invading the inferior vena cava – a European Society of Endocrine Surgeons (ESES) surveyLangenbecks Arch Surg2011397222523122134748
   PubMed Web of Science ®Google Scholar
• PacellaCMStasiRBizzarriGPercutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinomaEur J Radiol2008661889417498906
   PubMed Web of Science ®Google Scholar
• AdamPHahnerSHartmannMEpidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcomeMod Pathol201023121596160420693985
   PubMed Web of Science ®Google Scholar
• QuinklerMHahnerSWortmannSTreatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabineJ Clin Endocrinol Metab20089362057206218334586
   PubMed Web of Science ®Google Scholar
• GrossDJMunterGBitanMThe role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-REndocr Relat Cancer200613253554016728580
   PubMed Web of Science ®Google Scholar
• KroissMQuinklerMJohanssenSSunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trialJ Clin Endocrinol Metabolism2012971034953503
   PubMed Web of Science ®Google Scholar
• TaconLJPrichardRSSoonPSRobinsonBGClifton-BlighRJSidhuSBCurrent and Emerging Therapies for AdvancedAdrenocortical CarcinomaOncologist2011161364821212436
   PubMed Web of Science ®Google Scholar
• MacaulayVMMiddletonMREckhardtSGPhase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor- 1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumorsJ Clin Oncol201028153016
   Web of Science ®Google Scholar
• Astellas Pharma IncA Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma (GALACCTIC)ClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 [updated 2012]. Available from http://clinicaltrials.gov/show/NCT00924989. NLM identifier NCT00924989Accessed January 10, 2013
   Google Scholar
• WortmannSQuinklerMRitterCBevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinomaEur J Endocrinol2010162234935619903796
   PubMed Web of Science ®Google Scholar
• MemmottRMDennisPAAkt-dependent and -independent mechanisms of mTOR regulation in cancerCell Signal200921565666419166931
   PubMed Web of Science ®Google Scholar
• FraenkelMGueorguievMBarakDSalmonAGrossmanABGrossDJEverolimus therapy for progressive adrenocortical cancerEndocrine Epub February 16, 2013
   Web of Science ®Google Scholar
• NaingALoRussoPFuSInsulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinomaBr J Cancer2013108482683023412108
   PubMed Web of Science ®Google Scholar
• TissierFCavardCGroussinLMutations of beta-catenin in adrenocortical tumors: activation of the wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumorsCancer Res200565177622762716140927
   PubMed Web of Science ®Google Scholar
• IorioMVCroceCMMicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive reviewEMBO Mol Med20124314315922351564
   PubMed Web of Science ®Google Scholar
• JainMZhangLHeMInterleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinomaCancer2012118225698570822570059
   PubMed Web of Science ®Google Scholar